Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

ABSTRACT:

Background

Bladder carcinomas are immunogenic, and patients with bladder cancer benefit from immune checkpoint therapy. This is correlated to a high tumor mutation burden, which provides a higher number of neoepitopes that can be recognized by tumor-specific CD8⁺ T cells. Intravesical Bacillus Calmette-Guérin (BCG) is used to treat non-muscle invasive bladder cancer (NMIBC), but its mechanism of action remains elusive. Most lymphocytes appearing in the urine of BCG-treated patients are CD4⁺ T cells though preclinical studies showed that CD8⁺ T cells are also necessary for BCG treatment efficacy. It is currently unknown which proportion of patients with non-metastatic bladder cancer develop a spontaneous antitumor CD8⁺ response, and if BCG

SUBMITTER: Brochier W 

PROVIDER: S-EPMC12648094 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature